Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSosandar Regulatory News (SOS)

Share Price Information for Sosandar (SOS)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12.00
Bid: 11.50
Ask: 12.50
Change: 0.00 (0.00%)
Spread: 1.00 (8.696%)
Open: 12.00
High: 12.75
Low: 12.00
Prev. Close: 12.00
SOS Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Result of Meeting

1 Nov 2017 13:16

RNS Number : 2811V
Orogen PLC
01 November 2017
 

THIS ANNOUNCEMENT IS RESTRICTED AND IS NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM THE UNITED STATES, CANADA, AUSTRALIA, THE REPUBLIC OF SOUTH AFRICA, JAPAN OR ANY JURISDICTION IN WHICH THE SAME WOULD BE UNLAWFUL. THIS ANNOUNCEMENT SHALL NOT CONSTITUTE AN OFFER TO SELL OR ISSUE OR THE SOLICITATION TO BUY, SUBSCRIBE FOR OR OTHERWISE ACQUIRE ANY ORDINARY SHARES OF OROGEN PLC IN ANY JURISDICTION IN WHICH ANY SUCH OFFER OR SOLICITATION WOULD BE UNLAWFUL.

 

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

 

 

Orogen plc (to be renamed Sosandar plc)

("Orogen" or the "Company")

 

Result of General Meeting

Offer for Thread unconditional in all respects subject to Admission

 

Introduction

On 10 October 2017, Orogen announced the proposed acquisition of Thread 35 Ltd ("Thread"), for a total consideration of £6.3 million, pursuant to the Acquisition Agreement to acquire all the A Shares in Thread and the Offer to acquire all the B Shares in Thread.

The Acquisition was conditional, inter alia, upon the passing of certain resolutions ("Resolutions") set out in a notice of general meeting of Orogen to be held at 11.00 a.m. on 1 November 2017 ("General Meeting").

Terms and expressions used in this announcement shall, unless defined herein or unless the context otherwise requires, have the same meanings as given to them in the Admission Document, a copy of which is available on Orogen's website at www.orogen.co.uk.

General Meeting

Orogen is pleased to announce that, at the General Meeting held earlier today, all resolutions were duly passed.

Offer for Thread

As at 5.00 p.m. (London time) on 31 October 2017, being the closing date of the Offer for B Shares in Thread, Orogen had received valid acceptances in respect of 87,529 B Shares in Thread (representing 100 per cent. of the B Shares in issue).

Orogen is pleased to announce that the acceptance condition to the Offer has, therefore, been satisfied, and the Offer and the Acquisition of the A Shares in Thread are subject only to Admission, which is expected to take place at 8.00 a.m. on Thursday, 2 November 2017.

Consolidation

As a result of the passing of the Resolutions, the Consolidation will become effective as of 6.00 p.m. today and accordingly every ten Existing Ordinary Shares in the issued share capital of the Company shall be consolidated into one Ordinary Share, with such Ordinary Shares having the rights and being subject to the same restrictions (save as to nominal value) as the Existing Ordinary Shares in the capital of the Company as set out in the Articles.

Subscription and Placing

As announced on 10 October 2017, Orogen has raised £5.3 million (before expenses) through a conditional placing of 35,099,338 new Ordinary Shares at 15.1 pence per share, which will be used to finance the development of Thread and for working capital.

In addition, Orogen is pleased to announce that it has received valid subscriptions for 29,831,076 Subscription Shares, representing 96.3% of the Subscription Shares offered to Thread B Shareholders, raising £4,504,492 million for the Company. The Company has issued a further 1,150,358 Ordinary Shares at the Issue Price to raise £173,704 for the Company by means of a second subscription ("Second Subscription"). The Company has therefore raised a total of £4,678,196 through the issue of 30,981,434 new Ordinary Shares pursuant to the Subscription and the Second Subscription.

Admission

Orogen has applied to the London Stock Exchange for the Admission of its Enlarged Share Capital comprising 106,814,658 Ordinary Shares to trading on AIM, comprising:

 

· Ordinary Shares in issue following the Consolidation

26,472,816

· Placing Shares

35,099,338

· Consideration Shares

10,618,686

· Subscription Shares

29,831,076

· Fee Shares

3,311,258

· TP Shares

331,126

· Second Subscription

1,150,358

 

106,814,658

 

Admission is expected to become effective and dealings on AIM in Ordinary Shares are expected to commence at 8.00 a.m. on 2 November 2017.

The new Ordinary Shares will be traded under the ticker "SOS" and with the ISIN number GB00BDGS8G04. The figure of 106,814,658 Ordinary Shares may be used by Shareholders as the denominator for calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

Change of name

As a result of the Resolutions having been passed at the General Meeting, Orogen will change its name to Sosandar plc.

Change of Website

Following Admission, the website of the Company will change to www.sosandar.com.

Concert Party

On Admission, the Concert Party will hold, in aggregate, 45,496,658 Ordinary Shares, representing 42.6 per cent. of the Enlarged Ordinary Share Capital.

In the event that all of the Options held by members of the Concert Party following Admission are exercised and no other Options or Warrants are exercised, the Concert Party would hold up to 65,096,658 Ordinary Shares representing 51.5 per cent. of the so enlarged ordinary share capital.

Board changes

On Admission, Julie Lavington and Ali Hall, the Founders of Thread, will join the Board as joint Chief Executives. Nick Mustoe will also join the Board as a Non-Executive Director, and Steve Metcalfe will step down from the Board. Mark Collingbourne (Non-Executive Director of the Company) will assume the role of Finance Director and be supported in the role by James Bowling, the current Head of Finance for Thread. Bill Murray will become Non-Executive Chairman and Adam Reynolds will become a Non-Executive Director of the Company.

Following Admission, the Directors will have the following interests in Ordinary Shares and Options in the Company:

 

Name

Number of Ordinary Shares Shares

% of Enlarged Issued Share Capital

No of Options to subscribe for Ordinary Shares

Max Number of Ordinary Shares

% of the Enlarged Issued Share Capital (on a fully diluted basis)*

Bill Murray

345,107

0.3%

400,000

745,107

0.6%

Alison Hall

5,309,343

5.0%

8,400,000

13,709,343

10.8%

Julie Lavington

5,309,343

5.0%

8,400,000

13,709,343

10.8%

Mark Collingbourne

928,919

0.9%

400,000

1,328,919

1.0%

Adam Reynolds

1,960,802

1.8%

800,000

2,760,802

2.2%

Nick Mustoe

4,872,869

4.6%

400,000

5,272,869

4.2%

 

 

Enquiries:

 

 

Orogen plc

Adam Reynolds, Non-executive Chairman

C/o Walbrook

Cairn Financial Advisers LLP (Nominated Adviser)

Sandy Jamieson / Liam Murray / Richard Nash

+44 (0) 20 7213 0880

Turner Pope Investments (TPI) Limited (Broker)

Ben Turner / James Pope

+44 (0) 20 3621 4120

Walbrook (Public Relations and Investor Relations)

Paul Cornelius / Nick Rome

+44 (0) 20 7933 8780

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
ROMMMMGMFMMGNZM
Date   Source Headline
16th Apr 20247:00 amRNSFull Year Trading Update
10th Jan 20247:00 amRNSTrading Update
15th Dec 20237:00 amRNSBoard Changes
12th Dec 20237:00 amRNSHalf Year Results
29th Nov 20237:00 amRNSNotice of Results and Investor Presentations
9th Nov 20237:00 amRNSMello Investor Presentation
18th Oct 20237:00 amRNSTrading & Strategic Update
13th Oct 20237:00 amRNSNotice of Trading Update
5th Oct 20232:25 pmRNSHolding(s) in Company
21st Sep 20231:02 pmRNSResult of AGM
25th Aug 20239:45 amRNSNotice of AGM and Posting of Annual Report
11th Jul 20237:00 amRNSFinal Results
4th Jul 20237:00 amRNSNotice of Results and Investor Presentation
17th Apr 20233:13 pmRNSHolding(s) in Company
13th Apr 20232:28 pmRNSHolding(s) in Company
12th Apr 20237:00 amRNSTrading Update & Progress on Growth Strategy
16th Mar 20237:00 amRNSAppointment of Interim Non-Executive Chairman
3rd Mar 20238:12 amRNSDirector/PDMR Dealing
17th Feb 20233:54 pmRNSResult of Retail Offer
17th Feb 20237:00 amRNSClose of Retail Offer
14th Feb 20232:51 pmRNSHolding(s) in Company
13th Feb 202311:55 amRNSHolding(s) in Company
8th Feb 20234:40 pmRNSSecond Price Monitoring Extn
8th Feb 20234:35 pmRNSPrice Monitoring Extension
8th Feb 20231:30 pmRNSResult of Placing
8th Feb 20239:16 amRNSRetail Offer
8th Feb 20237:00 amRNSProposed Placing to raise a minimum of £4 million
6th Feb 20237:00 amRNSDeath of Director
23rd Jan 20237:00 amRNSNew Third Party Arrangement
10th Jan 20237:00 amRNSTrading Update
13th Dec 20227:00 amRNSHalf Year Results
17th Nov 20227:00 amRNSNotice of Results and Investor Presentation
15th Nov 20225:25 pmRNSAIM Rule 17 Schedule 2(g) Update
18th Oct 20227:00 amRNSHalf Year Trading Update
15th Sep 20223:24 pmRNSResult of AGM & Notice of Trading Update
22nd Aug 20227:00 amRNSNotice of AGM and Posting of Annual Report
18th Aug 20227:00 amRNSBoard Changes and Change of Auditor
12th Jul 20227:00 amRNSFinal Results
24th Jun 20227:00 amRNSNotice of Results and Investor Presentation
10th Jun 20223:31 pmRNSDirector/PDMR Shareholding
6th May 202212:55 pmRNSDirector/PDMR Dealing
14th Apr 20227:00 amRNSBoard Appointment
6th Apr 20222:05 pmRNSSecond Price Monitoring Extn
6th Apr 20222:00 pmRNSPrice Monitoring Extension
6th Apr 20227:00 amRNSTrading Update and New Third Party Arrangements
6th Jan 20227:00 amRNSTrading Update
20th Dec 20219:00 amRNSExercise of Warrants and Total Voting Rights
30th Nov 20217:00 amRNSHalf Year Results
12th Nov 20217:00 amRNSNotice of Results
7th Oct 202111:05 amRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.